

14 Aug 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: what Amgen's \$3.7bn ChemoCentryx buy means; Lilly's CEO on US drug pricing legislation; Pfizer's GBT acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 August 2022, including: what [Amgen, Inc.](#)'s \$3.7bn [ChemoCentryx, Inc.](#) buy means; [Eli Lilly and Company](#)'s CEO on US drug pricing legislation; [Pfizer Inc.](#)'s [Global Blood Therapeutics, Inc.](#) acquisition; new data for Amgen's KRAS inhibitor combo; and a major China ADC alliance for [Sanofi](#).

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Amgen's \\$3.7bn ChemoCentryx Buy May Help Offset Growing Pains](#)" - Scrip, 4 Aug, 2022.)

(Also see "[As Lilly's Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan](#)" - Scrip, 4 Aug, 2022.)

(Also see "[Pfizer's Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise](#)" - Scrip, 8 Aug, 2022.)

(Also see "[Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?](#)" - Scrip, 8 Aug,

2022.)

(Also see "[Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge](#)" - Scrip, 5 Aug, 2022.)

[Click here to explore this interactive content online](#) 